Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 02, 2025 09:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Announces Stock Split

CYCLACEL PHARMACEUTICALS ANNOUNCES STOCK SPLIT
June 20, 2025 16:30 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock

CYCLACEL PHARMACEUTICALS ANNOUNCES $3 MILLION PRIVATE PLACEMENT OFFERING OF CONVERTIBLE PREFERRED STOCK
April 02, 2025 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing...
March 24, 2025 07:30 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

KUALA LUMPUR, Malaysia, March 24, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer...
August 14, 2024 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

Cyclacel provides Q2 2024 financial results and business update on fadraciclib precision medicine strategy
August 07, 2024 09:15 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Release Second Quarter 2024 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
November 01, 2012 07:00 ET | Source: Cyclacel Pharmaceuticals, Inc.

Cyclacel Announces Publication of Phase 2 Results for Sapacitabine in Elderly AML Patients in the Lancet Oncology

Study Provides Support for SEAMLESS, an Ongoing, Phase 3, Registration-Directed Trial in Elderly Patients With Newly Diagnosed AML Updated Survival Data From a Pilot Study and Lead-In Phase of...